NYTimes: Why the Odds Are Stacked Against a Pro
Post# of 145743
Why the Odds Are Stacked Against a Promising New Covid Drug
A new drug quashes all coronavirus variants. But regulatory hurdles and a lack of funding make it unlikely to reach the U.S. market anytime soon.
The FDA is protecting Remdesivir now for Long Haulers and Pfizer Paxlovid.
Of the 208 patients recruited from 11 Finnish hospitals, 198 survived, of whom 181 (92%) completed follow-up. At one year, self-reported recovery occurred in 85% in remdesivir and 86% in standard of care (SoC) (RR 0.94, 95% CI 0.47-1.90). We infer no convincing difference between remdesivir and SoC in quality of life or symptom outcomes.
So if Remdesivir doesn't work and Paxlovid has to be taken in the first 4 days of an infection this means that the FDA is protecting drugs that don't work as first choice, which means there is NO CHANCE IN HELL for drugs that do work. This is why I suggest only coupling with BP for every indication. Plus the DOD is involved in Pandemic response as well which is another BP in.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)